These projects couple education with performance in order to heighten awareness of evidence-based treatment guidelines for the disease.
Robert C. Young, MD
The National Comprehensive Cancer Network® (NCCN) Oncology Research Program (ORP), in collaboration with Pfizer Independent Grants for Learning & Change (IGLC), has awarded 10 grants for project proposals to develop and adopt evidence-based initiatives to improve patient care and outcomes in metastatic breast cancer.
In 2015, NCCN ORP and Pfizer IGLC issued a Request for Proposals to any organization with an interest in improving patient care including academic and community hospitals.
“NCCN is proud of its ongoing collaboration with Pfizer IGLC to enhance the quality of treatment of people with metastatic breast cancer in both academic and community settings,” said Robert C. Young, MD, Interim Vice President, NCCN ORP. “Breast cancer is a leading cause of cancer death in women in the United States, and these projects indeed couple education with performance in order to heighten awareness and utilization of evidence-based treatment guidelines for the disease.”
“Metastatic breast cancer is a disease for which there currently is no cure, so improving patient care, support, and outcomes is critical,” said Julia Perkins Smith, MD, North America Medical Affairs Lead, Pfizer Oncology. “We are excited to collaborate with NCCN to support these 10 projects, which have the potential to make a meaningful impact on patients’ lives.”
The awardees responded to a Request for Proposals from NCCN ORP and Pfizer IGLC seeking concepts for initiatives focusing on the following areas where gaps in care currently exist:
The NCCN ORP, organized to obtain funding to support scientifically meritorious research studies at NCCN Member Institutions, was the lead organization for review and evaluation of applications.
A review committee, led by NCCN and including a medical representative from Pfizer, determined which proposals received funding. Grant funding is provided by Pfizer IGLC. ■